Recalls & Warnings June 20, 2002 Canadian Warning on Use of Bejai Bowyantan for Infants On June 14, 2002, Health Canada warned Canadians not to use Bejai Bowyantan for their young children and infants because it contains a substance with similar toxic properties to another substance known to cause serious adverse reactions and death in children
AOD 9604 is a synthetic fragment of human growth hormone (amino acids 176-191) that retains only the lipolytic domain and does not produce the anabolic, IGF-1-stimulating, or insulin-resistance effects of full-length HGH
After an injury, endogenous thymosin 4 is released by platelets and immune cells to protect tissues from further damage [4]
Peptides require medical oversight to help ensure safety, potency, and proper dosing
LiveWell ships across the United States and internationally, including Colombia, Mexico, Brazil, Argentina, Chile and Peru